SINUVA™ Sinus Implant

SINUVA™
(mometasone furoate) sinus implant

SINUVA™ (mometasone furoate) sinus implant, a nonsurgical targeted nasal polyp treatment option for adult patients with CRS who have had ethmoid sinus surgery

INDICATION

SINUVA™ Sinus Implant is a corticosteroid-eluting implant indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥ 18 years of age who have had ethmoid sinus surgery.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA™ Sinus Implant.

Read the full Important Safety Information

Discovering relief with SINUVA™ sinus implant

SINUVA is an option for the treatment of CRS with nasal polyps that’s been shown to provide effective relief, compared to daily steroid nasal spray^† alone in a clinical trial with 300 patients.^‡

Proven to shrink nasal polyps

Reduces symptoms of nasal obstruction and congestion

Reduces sinus obstruction and improves impaired sense of smell

Treatment with SINUVA™ resulted in fewer patients still needing sinus surgery^§

Key benefits of SINUVA™ sinus implant

SINUVA™ is a novel implant with a 2-in-1 mechanism that offers patients with nasal polyps symptom relief via:

Targeted delivery of 1350 µg of mometasone furoate to the ethmoid nasal polyps¹
Self-expanding, bioabsorbable design that softens over time¹
Continuous delivery of mometasone furoate over the course of 90 days^◊,1
Localized drug delivery minimizes reliance on patient compliance
Administered in a non-surgical, in-office procedure with local anesthesia¹
Mometasone furoate offers high potency and low systemic bioavailability¹

See clinical evidence

SINUVA™ sinus implant design¹

Width when crimped: 7.5 mm

Nominal length of 20 mm

Learn more about SINUVA™ sinus implant

First Name*

Last Name*

Company

Email*

Profession

Role

Primary Specialty

Country/Region*

City*

State*

Zip Code

Would you like to receive emails from Medtronic?*

I have read and agree with the Terms and Conditions*

Your information will be used and protected in accordance with our privacy statement.

Referenced path does not exist

† Mometasone furoate nasal spray.
‡ SINUVA™ was studied in a clinical trial with 201 patients who received SINUVA™ and daily steroid nasal spray, and 99 patients who were given daily steroid nasal spray alone. All patients were indicated for revision endoscopic sinus surgery at enrollment.
§ About 6 out of 10 patients treated with SINUVA™ and daily steroid nasal spray no longer needed repeat sinus surgery after 90 days compared to about 4 out of 10 patients treated with daily steroid nasal spray alone.
◊ SINUVA must be removed by day 90, or earlier per physician discretion.

SINUVA™ [Prescribing Information]. Menlo Park, CA: Intersect ENT; 2023.